Quick Answer
Artiva Biotherapeutics, Inc. reported Stockholders Equity of $109.97 million for fiscal year 2025.
Artiva Biotherapeutics, Inc. Stockholders Equity — Annual History
| Fiscal Year | Stockholders Equity | YoY Change |
|---|---|---|
| 2025 | $109.97M | -41.1% |
| 2024 | $186.64M | +215.2% |
| 2023 | -$162.01M | -15.2% |
| 2022 | -$140.70M | — |
Quarterly Stockholders Equity
| Quarter Ending | Stockholders Equity | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $129.22M | -35.7% | -13.3% |
| June 30, 2025 | $149.04M | +178.0% | -11.7% |
| March 31, 2025 | $168.78M | +196.6% | -9.6% |
| December 31, 2024 | $186.64M | +215.2% | -7.1% |
| September 30, 2024 | $201.00M | +232.7% | +205.2% |
| June 30, 2024 | -$191.10M | -16.3% | -9.4% |
| March 31, 2024 | -$174.67M | -12.3% | -7.8% |
| December 31, 2023 | -$162.01M | -15.2% | -7.0% |
- Artiva Biotherapeutics, Inc. showed a decrease of -41.1% in Stockholders Equity compared to the prior fiscal year.
- Over the 2022–2025 period, Artiva Biotherapeutics, Inc.’s stockholders equity has grown by 178.2% (from -$140.70 million to $109.97 million).
- The most recent figure is from Artiva Biotherapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 10, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: